Survodutide is an investigational GLP-1/glucagon dual agonist studied for weight and liver health. It is researched most often for Weight management, Liver health (MASH) and Metabolic health. Clinical trials — investigational. This guide walks through what Survodutide is, how it's studied, what it's commonly combined with, and — just as important — where the science stops. It's educational information only, not medical advice.
What is Survodutide?
Survodutide is a dual agonist of the GLP-1 and glucagon receptors under investigation for obesity and metabolic-associated fatty liver disease (MASH). It combines appetite regulation with effects on energy expenditure.
Also known as: BI 456906.
How does Survodutide work?
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors. Combining appetite regulation with glucagon-driven energy expenditure, it is under study for obesity and for metabolic-associated fatty liver disease (MASH).
What is Survodutide researched for?
In the research and community discussion, Survodutide comes up most often in connection with Weight management, Liver health (MASH) and Metabolic health. Remember that "researched for" is not the same as "proven to treat" — these are the directions the science has explored, not established outcomes.
- Weight management
- Liver health (MASH)
- Metabolic health
What does the research actually show?
Clinical trials — investigational. The honest framing matters here: promising mechanisms and early results are genuinely interesting, but they are not the same as proven, approved therapy. Anyone presenting Survodutide as a guaranteed treatment is getting ahead of the evidence.
Safety and considerations
Not approved. Investigational compound; use only under medical supervision. Because the responsible framing is educational rather than prescriptive, Selpho provides no dosing, protocols, or purchase links, and always points back to a licensed professional for any decision. If you are dealing with a real health concern, that professional — not a peptide — is where planning should start.
Where to learn more about Survodutide
To go deeper, see the Survodutide library page for a quick reference; published research on PubMed; Selpho's free AI Peptide Advisor to see where Survodutide might fit your goals.
Frequently asked questions
Weight management, liver health (MASH), and broader metabolic outcomes. It is investigational.
It activates both GLP-1 and glucagon receptors, whereas semaglutide targets GLP-1 alone. It is still in clinical development.
No. It is investigational and not approved for use.
Not sure if Survodutide fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis guide is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.